Fig. 4From: The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatmentsAchieving fixed targets: combinations of annual treatments and susceptible vaccinations that achieve a 50Â % relative prevalence reduction target after 10Â years (grey) and 15Â years (black) with various vaccine efficacies (30, 60 and 90Â %) for a 50Â % initial chronic HCV prevalence among PWID. HCV hepatitis C virus, PWID people who inject drugsBack to article page